Contractor
VENATORX PHARMACEUTICALS INC
- UEI
- MBBKNBU5DCC6
- Resolved by
- uei
- Confidence
- 1.000
Active from Sep 19, 2016 to Jul 31, 2026.
Recent awards
| Award | Agency | Place | First action | Current value |
|---|---|---|---|---|
| HHSN272201600029C IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | Department of Health and Human Services | PA | Sep 19, 2016 | $48,517,079 |
| 75A50119C00007 THE PURPOSE OF THIS BILATERAL MODIFICATION DE-OBLIGATES CANCELING YEAR FUNDS FROM REQUISITION OS256610 IN THE AMOUNT OF (-$615,177.10) FROM CLIN0006 AND FROM REQUISITION OS257789 IN THE AMOUNT OF (-$222.20) FROM CLIN00001. | Department of Health and Human Services | PA | May 26, 2026 | $131,756,814 |
| 75A50122C00080 THE PURPOSE OF THIS MODIFICATION IS TO REPORT INFORMATION VIA FPDS FOR CONTRACTS BEING ALIGNED WITH THE PRESIDENTIAL COST SAVINGS INITIATIVE. EOI: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING | Department of Health and Human Services | PA | May 13, 2026 | $72,141,707 |
| HDTRA117C0070 NEW PBP INHIBITORS IMPERVIOUS TO BETA-LACTAMASES | Department of Defense | PA | Apr 30, 2026 | $14,716,733 |
Sources and method
Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.
Totals sum obligations across every award attributed to this contractor. Obligations are cumulative funding actions, not the value of work delivered.
- 1Awards are attributed by Unique Entity Identifier MBBKNBU5DCC6, the government's own recipient identifier, not by name matching.
- 2Award records from USAspending.gov, last refreshed Aug 10, 2026.